Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRIS: Imatinib vs Interferon-alpha + Cytarabine in CML
NCT00006343Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2000
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: Time to Treatment Failure and Overall Survival. Started Jun 2000; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00006343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006343.